Global Protein Therapeutic Market

Protein Therapeutic Comprehensive Study by Type (Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon, Human Growth Hormone, Follicle Stimulating Hormone), Application (Cancer, Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Hormonal Disorders, Genetic Disorders, Others), End User (Pharmaceutical and Biotechnology Companies, Healthcare service providers, Research Organizations and Academic Research Institutes, Other) Players and Region - Global Market Outlook to 2026

Protein Therapeutic Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Protein Therapeutic refers to proteins which are engineered in the laboratory so it can be used in pharmaceutical use. These are an important class of drugs which serves patient in need of novel therapies. Protein Therapeutics treat a wide array of clinical indication which includes cancer, infectious diseases, genetic disorder and metabolic disorder.
This growth is primarily driven by Increase In Prevalence Of Chronic Diseases, Government Initiative to Improve The Healthcare Services, Rising Demand For High-Quality Recombinant Therapeutics and Rising Research Activities On Protein Therapeutics.

Globally, a noticeable market trend is evident Technological Advancements Such As Mass Spectrometry, Advances In Molecular Genetics, And Progress In Production Technologies. The Drug Retail sector in the North America region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Vendors, such as Merck KGaA (Germany), Thermo Fisher Scientific Inc. (United States), Becton, Dickinson & Company (United States), Agilent Technologies, Inc. (United States), QIAGEN N.V. (Netherlands), Takara Bio Inc. (Japan), Lonza Group Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (United States), GenScript Biotech Corporation (China), Lucigen Corporation (United States), Synthetic Genomics Inc. (United States), Promega Corporation (United States), New England Biolabs, Inc. (United States) and Sengenics (Singapore) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Market Drivers
  • Increase In Prevalence Of Chronic Diseases
  • Government Initiative to Improve The Healthcare Services
  • Rising Demand For High-Quality Recombinant Therapeutics
  • Rising Research Activities On Protein Therapeutics

Market Trend
  • Technological Advancements Such As Mass Spectrometry, Advances In Molecular Genetics, And Progress In Production Technologies

Restraints
  • High Costs Associated With Therapeutic Proteins
  • Binding Government Regulations For Protein Therapeutics

Opportunities
Adoption Of Protein Therapeutics For Unique Indications
Challenges
High Cost of Production and Treatment and Competition from Biosimilars

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Vendors landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Protein Therapeutic Study Sheds Light on
— The Protein Therapeutic Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Protein Therapeutic industry Vendors. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Protein Therapeutic industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Vendors can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Monoclonal Antibodies
  • Insulin
  • Fusion Protein
  • Erythropoietin
  • Interferon
  • Human Growth Hormone
  • Follicle Stimulating Hormone
By Application
  • Cancer
  • Metabolic Disorders
  • Immunologic Disorders
  • Hematological Disorders
  • Hormonal Disorders
  • Genetic Disorders
  • Others
By End User
  • Pharmaceutical and Biotechnology Companies
  • Healthcare service providers
  • Research Organizations and Academic Research Institutes
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase In Prevalence Of Chronic Diseases
      • 3.2.2. Government Initiative to Improve The Healthcare Services
      • 3.2.3. Rising Demand For High-Quality Recombinant Therapeutics
      • 3.2.4. Rising Research Activities On Protein Therapeutics
    • 3.3. Market Challenges
      • 3.3.1. High Cost of Production and Treatment
      • 3.3.2. Competition from Biosimilars
    • 3.4. Market Trends
      • 3.4.1. Technological Advancements Such As Mass Spectrometry, Advances In Molecular Genetics, And Progress In Production Technologies
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Protein Therapeutic, by Type, Application, End User and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Protein Therapeutic (Value)
      • 5.2.1. Global Protein Therapeutic by: Type (Value)
        • 5.2.1.1. Monoclonal Antibodies
        • 5.2.1.2. Insulin
        • 5.2.1.3. Fusion Protein
        • 5.2.1.4. Erythropoietin
        • 5.2.1.5. Interferon
        • 5.2.1.6. Human Growth Hormone
        • 5.2.1.7. Follicle Stimulating Hormone
      • 5.2.2. Global Protein Therapeutic by: Application (Value)
        • 5.2.2.1. Cancer
        • 5.2.2.2. Metabolic Disorders
        • 5.2.2.3. Immunologic Disorders
        • 5.2.2.4. Hematological Disorders
        • 5.2.2.5. Hormonal Disorders
        • 5.2.2.6. Genetic Disorders
        • 5.2.2.7. Others
      • 5.2.3. Global Protein Therapeutic by: End User (Value)
        • 5.2.3.1. Pharmaceutical and Biotechnology Companies
        • 5.2.3.2. Healthcare service providers
        • 5.2.3.3. Research Organizations and Academic Research Institutes
        • 5.2.3.4. Other
      • 5.2.4. Global Protein Therapeutic Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Protein Therapeutic (Price)
      • 5.3.1. Global Protein Therapeutic by: Type (Price)
  • 6. Protein Therapeutic: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Merck KGaA (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Thermo Fisher Scientific Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Becton, Dickinson & Company (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Agilent Technologies, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. QIAGEN N.V. (Netherlands)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Takara Bio Inc. (Japan)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Lonza Group Ltd. (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bio-Rad Laboratories, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. GenScript Biotech Corporation (China)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Lucigen Corporation (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Synthetic Genomics Inc. (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Promega Corporation (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. New England Biolabs, Inc. (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. Sengenics (Singapore)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
  • 7. Global Protein Therapeutic Sale, by Type, Application, End User and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Protein Therapeutic (Value)
      • 7.2.1. Global Protein Therapeutic by: Type (Value)
        • 7.2.1.1. Monoclonal Antibodies
        • 7.2.1.2. Insulin
        • 7.2.1.3. Fusion Protein
        • 7.2.1.4. Erythropoietin
        • 7.2.1.5. Interferon
        • 7.2.1.6. Human Growth Hormone
        • 7.2.1.7. Follicle Stimulating Hormone
      • 7.2.2. Global Protein Therapeutic by: Application (Value)
        • 7.2.2.1. Cancer
        • 7.2.2.2. Metabolic Disorders
        • 7.2.2.3. Immunologic Disorders
        • 7.2.2.4. Hematological Disorders
        • 7.2.2.5. Hormonal Disorders
        • 7.2.2.6. Genetic Disorders
        • 7.2.2.7. Others
      • 7.2.3. Global Protein Therapeutic by: End User (Value)
        • 7.2.3.1. Pharmaceutical and Biotechnology Companies
        • 7.2.3.2. Healthcare service providers
        • 7.2.3.3. Research Organizations and Academic Research Institutes
        • 7.2.3.4. Other
      • 7.2.4. Global Protein Therapeutic Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Protein Therapeutic (Price)
      • 7.3.1. Global Protein Therapeutic by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Protein Therapeutic: by Type(USD Million)
  • Table 2. Protein Therapeutic Monoclonal Antibodies , by Region USD Million (2015-2020)
  • Table 3. Protein Therapeutic Insulin , by Region USD Million (2015-2020)
  • Table 4. Protein Therapeutic Fusion Protein , by Region USD Million (2015-2020)
  • Table 5. Protein Therapeutic Erythropoietin , by Region USD Million (2015-2020)
  • Table 6. Protein Therapeutic Interferon , by Region USD Million (2015-2020)
  • Table 7. Protein Therapeutic Human Growth Hormone , by Region USD Million (2015-2020)
  • Table 8. Protein Therapeutic Follicle Stimulating Hormone , by Region USD Million (2015-2020)
  • Table 9. Protein Therapeutic: by Application(USD Million)
  • Table 10. Protein Therapeutic Cancer , by Region USD Million (2015-2020)
  • Table 11. Protein Therapeutic Metabolic Disorders , by Region USD Million (2015-2020)
  • Table 12. Protein Therapeutic Immunologic Disorders , by Region USD Million (2015-2020)
  • Table 13. Protein Therapeutic Hematological Disorders , by Region USD Million (2015-2020)
  • Table 14. Protein Therapeutic Hormonal Disorders , by Region USD Million (2015-2020)
  • Table 15. Protein Therapeutic Genetic Disorders , by Region USD Million (2015-2020)
  • Table 16. Protein Therapeutic Others , by Region USD Million (2015-2020)
  • Table 17. Protein Therapeutic: by End User(USD Million)
  • Table 18. Protein Therapeutic Pharmaceutical and Biotechnology Companies , by Region USD Million (2015-2020)
  • Table 19. Protein Therapeutic Healthcare service providers , by Region USD Million (2015-2020)
  • Table 20. Protein Therapeutic Research Organizations and Academic Research Institutes , by Region USD Million (2015-2020)
  • Table 21. Protein Therapeutic Other , by Region USD Million (2015-2020)
  • Table 22. South America Protein Therapeutic, by Country USD Million (2015-2020)
  • Table 23. South America Protein Therapeutic, by Type USD Million (2015-2020)
  • Table 24. South America Protein Therapeutic, by Application USD Million (2015-2020)
  • Table 25. South America Protein Therapeutic, by End User USD Million (2015-2020)
  • Table 26. Brazil Protein Therapeutic, by Type USD Million (2015-2020)
  • Table 27. Brazil Protein Therapeutic, by Application USD Million (2015-2020)
  • Table 28. Brazil Protein Therapeutic, by End User USD Million (2015-2020)
  • Table 29. Argentina Protein Therapeutic, by Type USD Million (2015-2020)
  • Table 30. Argentina Protein Therapeutic, by Application USD Million (2015-2020)
  • Table 31. Argentina Protein Therapeutic, by End User USD Million (2015-2020)
  • Table 32. Rest of South America Protein Therapeutic, by Type USD Million (2015-2020)
  • Table 33. Rest of South America Protein Therapeutic, by Application USD Million (2015-2020)
  • Table 34. Rest of South America Protein Therapeutic, by End User USD Million (2015-2020)
  • Table 35. Asia Pacific Protein Therapeutic, by Country USD Million (2015-2020)
  • Table 36. Asia Pacific Protein Therapeutic, by Type USD Million (2015-2020)
  • Table 37. Asia Pacific Protein Therapeutic, by Application USD Million (2015-2020)
  • Table 38. Asia Pacific Protein Therapeutic, by End User USD Million (2015-2020)
  • Table 39. China Protein Therapeutic, by Type USD Million (2015-2020)
  • Table 40. China Protein Therapeutic, by Application USD Million (2015-2020)
  • Table 41. China Protein Therapeutic, by End User USD Million (2015-2020)
  • Table 42. Japan Protein Therapeutic, by Type USD Million (2015-2020)
  • Table 43. Japan Protein Therapeutic, by Application USD Million (2015-2020)
  • Table 44. Japan Protein Therapeutic, by End User USD Million (2015-2020)
  • Table 45. India Protein Therapeutic, by Type USD Million (2015-2020)
  • Table 46. India Protein Therapeutic, by Application USD Million (2015-2020)
  • Table 47. India Protein Therapeutic, by End User USD Million (2015-2020)
  • Table 48. South Korea Protein Therapeutic, by Type USD Million (2015-2020)
  • Table 49. South Korea Protein Therapeutic, by Application USD Million (2015-2020)
  • Table 50. South Korea Protein Therapeutic, by End User USD Million (2015-2020)
  • Table 51. Taiwan Protein Therapeutic, by Type USD Million (2015-2020)
  • Table 52. Taiwan Protein Therapeutic, by Application USD Million (2015-2020)
  • Table 53. Taiwan Protein Therapeutic, by End User USD Million (2015-2020)
  • Table 54. Australia Protein Therapeutic, by Type USD Million (2015-2020)
  • Table 55. Australia Protein Therapeutic, by Application USD Million (2015-2020)
  • Table 56. Australia Protein Therapeutic, by End User USD Million (2015-2020)
  • Table 57. Rest of Asia-Pacific Protein Therapeutic, by Type USD Million (2015-2020)
  • Table 58. Rest of Asia-Pacific Protein Therapeutic, by Application USD Million (2015-2020)
  • Table 59. Rest of Asia-Pacific Protein Therapeutic, by End User USD Million (2015-2020)
  • Table 60. Europe Protein Therapeutic, by Country USD Million (2015-2020)
  • Table 61. Europe Protein Therapeutic, by Type USD Million (2015-2020)
  • Table 62. Europe Protein Therapeutic, by Application USD Million (2015-2020)
  • Table 63. Europe Protein Therapeutic, by End User USD Million (2015-2020)
  • Table 64. Germany Protein Therapeutic, by Type USD Million (2015-2020)
  • Table 65. Germany Protein Therapeutic, by Application USD Million (2015-2020)
  • Table 66. Germany Protein Therapeutic, by End User USD Million (2015-2020)
  • Table 67. France Protein Therapeutic, by Type USD Million (2015-2020)
  • Table 68. France Protein Therapeutic, by Application USD Million (2015-2020)
  • Table 69. France Protein Therapeutic, by End User USD Million (2015-2020)
  • Table 70. Italy Protein Therapeutic, by Type USD Million (2015-2020)
  • Table 71. Italy Protein Therapeutic, by Application USD Million (2015-2020)
  • Table 72. Italy Protein Therapeutic, by End User USD Million (2015-2020)
  • Table 73. United Kingdom Protein Therapeutic, by Type USD Million (2015-2020)
  • Table 74. United Kingdom Protein Therapeutic, by Application USD Million (2015-2020)
  • Table 75. United Kingdom Protein Therapeutic, by End User USD Million (2015-2020)
  • Table 76. Netherlands Protein Therapeutic, by Type USD Million (2015-2020)
  • Table 77. Netherlands Protein Therapeutic, by Application USD Million (2015-2020)
  • Table 78. Netherlands Protein Therapeutic, by End User USD Million (2015-2020)
  • Table 79. Rest of Europe Protein Therapeutic, by Type USD Million (2015-2020)
  • Table 80. Rest of Europe Protein Therapeutic, by Application USD Million (2015-2020)
  • Table 81. Rest of Europe Protein Therapeutic, by End User USD Million (2015-2020)
  • Table 82. MEA Protein Therapeutic, by Country USD Million (2015-2020)
  • Table 83. MEA Protein Therapeutic, by Type USD Million (2015-2020)
  • Table 84. MEA Protein Therapeutic, by Application USD Million (2015-2020)
  • Table 85. MEA Protein Therapeutic, by End User USD Million (2015-2020)
  • Table 86. Middle East Protein Therapeutic, by Type USD Million (2015-2020)
  • Table 87. Middle East Protein Therapeutic, by Application USD Million (2015-2020)
  • Table 88. Middle East Protein Therapeutic, by End User USD Million (2015-2020)
  • Table 89. Africa Protein Therapeutic, by Type USD Million (2015-2020)
  • Table 90. Africa Protein Therapeutic, by Application USD Million (2015-2020)
  • Table 91. Africa Protein Therapeutic, by End User USD Million (2015-2020)
  • Table 92. North America Protein Therapeutic, by Country USD Million (2015-2020)
  • Table 93. North America Protein Therapeutic, by Type USD Million (2015-2020)
  • Table 94. North America Protein Therapeutic, by Application USD Million (2015-2020)
  • Table 95. North America Protein Therapeutic, by End User USD Million (2015-2020)
  • Table 96. United States Protein Therapeutic, by Type USD Million (2015-2020)
  • Table 97. United States Protein Therapeutic, by Application USD Million (2015-2020)
  • Table 98. United States Protein Therapeutic, by End User USD Million (2015-2020)
  • Table 99. Canada Protein Therapeutic, by Type USD Million (2015-2020)
  • Table 100. Canada Protein Therapeutic, by Application USD Million (2015-2020)
  • Table 101. Canada Protein Therapeutic, by End User USD Million (2015-2020)
  • Table 102. Mexico Protein Therapeutic, by Type USD Million (2015-2020)
  • Table 103. Mexico Protein Therapeutic, by Application USD Million (2015-2020)
  • Table 104. Mexico Protein Therapeutic, by End User USD Million (2015-2020)
  • Table 105. Protein Therapeutic: by Type(USD/Units)
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Company Basic Information, Sales Area and Its Competitors
  • Table 113. Company Basic Information, Sales Area and Its Competitors
  • Table 114. Company Basic Information, Sales Area and Its Competitors
  • Table 115. Company Basic Information, Sales Area and Its Competitors
  • Table 116. Company Basic Information, Sales Area and Its Competitors
  • Table 117. Company Basic Information, Sales Area and Its Competitors
  • Table 118. Company Basic Information, Sales Area and Its Competitors
  • Table 119. Company Basic Information, Sales Area and Its Competitors
  • Table 120. Protein Therapeutic: by Type(USD Million)
  • Table 121. Protein Therapeutic Monoclonal Antibodies , by Region USD Million (2021-2026)
  • Table 122. Protein Therapeutic Insulin , by Region USD Million (2021-2026)
  • Table 123. Protein Therapeutic Fusion Protein , by Region USD Million (2021-2026)
  • Table 124. Protein Therapeutic Erythropoietin , by Region USD Million (2021-2026)
  • Table 125. Protein Therapeutic Interferon , by Region USD Million (2021-2026)
  • Table 126. Protein Therapeutic Human Growth Hormone , by Region USD Million (2021-2026)
  • Table 127. Protein Therapeutic Follicle Stimulating Hormone , by Region USD Million (2021-2026)
  • Table 128. Protein Therapeutic: by Application(USD Million)
  • Table 129. Protein Therapeutic Cancer , by Region USD Million (2021-2026)
  • Table 130. Protein Therapeutic Metabolic Disorders , by Region USD Million (2021-2026)
  • Table 131. Protein Therapeutic Immunologic Disorders , by Region USD Million (2021-2026)
  • Table 132. Protein Therapeutic Hematological Disorders , by Region USD Million (2021-2026)
  • Table 133. Protein Therapeutic Hormonal Disorders , by Region USD Million (2021-2026)
  • Table 134. Protein Therapeutic Genetic Disorders , by Region USD Million (2021-2026)
  • Table 135. Protein Therapeutic Others , by Region USD Million (2021-2026)
  • Table 136. Protein Therapeutic: by End User(USD Million)
  • Table 137. Protein Therapeutic Pharmaceutical and Biotechnology Companies , by Region USD Million (2021-2026)
  • Table 138. Protein Therapeutic Healthcare service providers , by Region USD Million (2021-2026)
  • Table 139. Protein Therapeutic Research Organizations and Academic Research Institutes , by Region USD Million (2021-2026)
  • Table 140. Protein Therapeutic Other , by Region USD Million (2021-2026)
  • Table 141. South America Protein Therapeutic, by Country USD Million (2021-2026)
  • Table 142. South America Protein Therapeutic, by Type USD Million (2021-2026)
  • Table 143. South America Protein Therapeutic, by Application USD Million (2021-2026)
  • Table 144. South America Protein Therapeutic, by End User USD Million (2021-2026)
  • Table 145. Brazil Protein Therapeutic, by Type USD Million (2021-2026)
  • Table 146. Brazil Protein Therapeutic, by Application USD Million (2021-2026)
  • Table 147. Brazil Protein Therapeutic, by End User USD Million (2021-2026)
  • Table 148. Argentina Protein Therapeutic, by Type USD Million (2021-2026)
  • Table 149. Argentina Protein Therapeutic, by Application USD Million (2021-2026)
  • Table 150. Argentina Protein Therapeutic, by End User USD Million (2021-2026)
  • Table 151. Rest of South America Protein Therapeutic, by Type USD Million (2021-2026)
  • Table 152. Rest of South America Protein Therapeutic, by Application USD Million (2021-2026)
  • Table 153. Rest of South America Protein Therapeutic, by End User USD Million (2021-2026)
  • Table 154. Asia Pacific Protein Therapeutic, by Country USD Million (2021-2026)
  • Table 155. Asia Pacific Protein Therapeutic, by Type USD Million (2021-2026)
  • Table 156. Asia Pacific Protein Therapeutic, by Application USD Million (2021-2026)
  • Table 157. Asia Pacific Protein Therapeutic, by End User USD Million (2021-2026)
  • Table 158. China Protein Therapeutic, by Type USD Million (2021-2026)
  • Table 159. China Protein Therapeutic, by Application USD Million (2021-2026)
  • Table 160. China Protein Therapeutic, by End User USD Million (2021-2026)
  • Table 161. Japan Protein Therapeutic, by Type USD Million (2021-2026)
  • Table 162. Japan Protein Therapeutic, by Application USD Million (2021-2026)
  • Table 163. Japan Protein Therapeutic, by End User USD Million (2021-2026)
  • Table 164. India Protein Therapeutic, by Type USD Million (2021-2026)
  • Table 165. India Protein Therapeutic, by Application USD Million (2021-2026)
  • Table 166. India Protein Therapeutic, by End User USD Million (2021-2026)
  • Table 167. South Korea Protein Therapeutic, by Type USD Million (2021-2026)
  • Table 168. South Korea Protein Therapeutic, by Application USD Million (2021-2026)
  • Table 169. South Korea Protein Therapeutic, by End User USD Million (2021-2026)
  • Table 170. Taiwan Protein Therapeutic, by Type USD Million (2021-2026)
  • Table 171. Taiwan Protein Therapeutic, by Application USD Million (2021-2026)
  • Table 172. Taiwan Protein Therapeutic, by End User USD Million (2021-2026)
  • Table 173. Australia Protein Therapeutic, by Type USD Million (2021-2026)
  • Table 174. Australia Protein Therapeutic, by Application USD Million (2021-2026)
  • Table 175. Australia Protein Therapeutic, by End User USD Million (2021-2026)
  • Table 176. Rest of Asia-Pacific Protein Therapeutic, by Type USD Million (2021-2026)
  • Table 177. Rest of Asia-Pacific Protein Therapeutic, by Application USD Million (2021-2026)
  • Table 178. Rest of Asia-Pacific Protein Therapeutic, by End User USD Million (2021-2026)
  • Table 179. Europe Protein Therapeutic, by Country USD Million (2021-2026)
  • Table 180. Europe Protein Therapeutic, by Type USD Million (2021-2026)
  • Table 181. Europe Protein Therapeutic, by Application USD Million (2021-2026)
  • Table 182. Europe Protein Therapeutic, by End User USD Million (2021-2026)
  • Table 183. Germany Protein Therapeutic, by Type USD Million (2021-2026)
  • Table 184. Germany Protein Therapeutic, by Application USD Million (2021-2026)
  • Table 185. Germany Protein Therapeutic, by End User USD Million (2021-2026)
  • Table 186. France Protein Therapeutic, by Type USD Million (2021-2026)
  • Table 187. France Protein Therapeutic, by Application USD Million (2021-2026)
  • Table 188. France Protein Therapeutic, by End User USD Million (2021-2026)
  • Table 189. Italy Protein Therapeutic, by Type USD Million (2021-2026)
  • Table 190. Italy Protein Therapeutic, by Application USD Million (2021-2026)
  • Table 191. Italy Protein Therapeutic, by End User USD Million (2021-2026)
  • Table 192. United Kingdom Protein Therapeutic, by Type USD Million (2021-2026)
  • Table 193. United Kingdom Protein Therapeutic, by Application USD Million (2021-2026)
  • Table 194. United Kingdom Protein Therapeutic, by End User USD Million (2021-2026)
  • Table 195. Netherlands Protein Therapeutic, by Type USD Million (2021-2026)
  • Table 196. Netherlands Protein Therapeutic, by Application USD Million (2021-2026)
  • Table 197. Netherlands Protein Therapeutic, by End User USD Million (2021-2026)
  • Table 198. Rest of Europe Protein Therapeutic, by Type USD Million (2021-2026)
  • Table 199. Rest of Europe Protein Therapeutic, by Application USD Million (2021-2026)
  • Table 200. Rest of Europe Protein Therapeutic, by End User USD Million (2021-2026)
  • Table 201. MEA Protein Therapeutic, by Country USD Million (2021-2026)
  • Table 202. MEA Protein Therapeutic, by Type USD Million (2021-2026)
  • Table 203. MEA Protein Therapeutic, by Application USD Million (2021-2026)
  • Table 204. MEA Protein Therapeutic, by End User USD Million (2021-2026)
  • Table 205. Middle East Protein Therapeutic, by Type USD Million (2021-2026)
  • Table 206. Middle East Protein Therapeutic, by Application USD Million (2021-2026)
  • Table 207. Middle East Protein Therapeutic, by End User USD Million (2021-2026)
  • Table 208. Africa Protein Therapeutic, by Type USD Million (2021-2026)
  • Table 209. Africa Protein Therapeutic, by Application USD Million (2021-2026)
  • Table 210. Africa Protein Therapeutic, by End User USD Million (2021-2026)
  • Table 211. North America Protein Therapeutic, by Country USD Million (2021-2026)
  • Table 212. North America Protein Therapeutic, by Type USD Million (2021-2026)
  • Table 213. North America Protein Therapeutic, by Application USD Million (2021-2026)
  • Table 214. North America Protein Therapeutic, by End User USD Million (2021-2026)
  • Table 215. United States Protein Therapeutic, by Type USD Million (2021-2026)
  • Table 216. United States Protein Therapeutic, by Application USD Million (2021-2026)
  • Table 217. United States Protein Therapeutic, by End User USD Million (2021-2026)
  • Table 218. Canada Protein Therapeutic, by Type USD Million (2021-2026)
  • Table 219. Canada Protein Therapeutic, by Application USD Million (2021-2026)
  • Table 220. Canada Protein Therapeutic, by End User USD Million (2021-2026)
  • Table 221. Mexico Protein Therapeutic, by Type USD Million (2021-2026)
  • Table 222. Mexico Protein Therapeutic, by Application USD Million (2021-2026)
  • Table 223. Mexico Protein Therapeutic, by End User USD Million (2021-2026)
  • Table 224. Protein Therapeutic: by Type(USD/Units)
  • Table 225. Research Programs/Design for This Report
  • Table 226. Key Data Information from Secondary Sources
  • Table 227. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Protein Therapeutic: by Type USD Million (2015-2020)
  • Figure 5. Global Protein Therapeutic: by Application USD Million (2015-2020)
  • Figure 6. Global Protein Therapeutic: by End User USD Million (2015-2020)
  • Figure 7. South America Protein Therapeutic Share (%), by Country
  • Figure 8. Asia Pacific Protein Therapeutic Share (%), by Country
  • Figure 9. Europe Protein Therapeutic Share (%), by Country
  • Figure 10. MEA Protein Therapeutic Share (%), by Country
  • Figure 11. North America Protein Therapeutic Share (%), by Country
  • Figure 12. Global Protein Therapeutic: by Type USD/Units (2015-2020)
  • Figure 13. Global Protein Therapeutic share by Players 2020 (%)
  • Figure 14. Global Protein Therapeutic share by Players (Top 3) 2020(%)
  • Figure 15. Global Protein Therapeutic share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 18. Merck KGaA (Germany) Revenue: by Geography 2020
  • Figure 19. Thermo Fisher Scientific Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Thermo Fisher Scientific Inc. (United States) Revenue: by Geography 2020
  • Figure 21. Becton, Dickinson & Company (United States) Revenue, Net Income and Gross profit
  • Figure 22. Becton, Dickinson & Company (United States) Revenue: by Geography 2020
  • Figure 23. Agilent Technologies, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Agilent Technologies, Inc. (United States) Revenue: by Geography 2020
  • Figure 25. QIAGEN N.V. (Netherlands) Revenue, Net Income and Gross profit
  • Figure 26. QIAGEN N.V. (Netherlands) Revenue: by Geography 2020
  • Figure 27. Takara Bio Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 28. Takara Bio Inc. (Japan) Revenue: by Geography 2020
  • Figure 29. Lonza Group Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 30. Lonza Group Ltd. (Switzerland) Revenue: by Geography 2020
  • Figure 31. Bio-Rad Laboratories, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Bio-Rad Laboratories, Inc. (United States) Revenue: by Geography 2020
  • Figure 33. GenScript Biotech Corporation (China) Revenue, Net Income and Gross profit
  • Figure 34. GenScript Biotech Corporation (China) Revenue: by Geography 2020
  • Figure 35. Lucigen Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 36. Lucigen Corporation (United States) Revenue: by Geography 2020
  • Figure 37. Synthetic Genomics Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 38. Synthetic Genomics Inc. (United States) Revenue: by Geography 2020
  • Figure 39. Promega Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 40. Promega Corporation (United States) Revenue: by Geography 2020
  • Figure 41. New England Biolabs, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 42. New England Biolabs, Inc. (United States) Revenue: by Geography 2020
  • Figure 43. Sengenics (Singapore) Revenue, Net Income and Gross profit
  • Figure 44. Sengenics (Singapore) Revenue: by Geography 2020
  • Figure 45. Global Protein Therapeutic: by Type USD Million (2021-2026)
  • Figure 46. Global Protein Therapeutic: by Application USD Million (2021-2026)
  • Figure 47. Global Protein Therapeutic: by End User USD Million (2021-2026)
  • Figure 48. South America Protein Therapeutic Share (%), by Country
  • Figure 49. Asia Pacific Protein Therapeutic Share (%), by Country
  • Figure 50. Europe Protein Therapeutic Share (%), by Country
  • Figure 51. MEA Protein Therapeutic Share (%), by Country
  • Figure 52. North America Protein Therapeutic Share (%), by Country
  • Figure 53. Global Protein Therapeutic: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • Merck KGaA (Germany)
  • Thermo Fisher Scientific Inc. (United States)
  • Becton, Dickinson & Company (United States)
  • Agilent Technologies, Inc. (United States)
  • QIAGEN N.V. (Netherlands)
  • Takara Bio Inc. (Japan)
  • Lonza Group Ltd. (Switzerland)
  • Bio-Rad Laboratories, Inc. (United States)
  • GenScript Biotech Corporation (China)
  • Lucigen Corporation (United States)
  • Synthetic Genomics Inc. (United States)
  • Promega Corporation (United States)
  • New England Biolabs, Inc. (United States)
  • Sengenics (Singapore)
Additional players considered in the study are as follows:
ARTES Biotechnology GmbH (Germany) , Addgene Inc. (United States) , LifeSensors Inc. (United States) , Accelagen Inc. (United States) , Geneva Biotech (Switzerland) , Viva Biotech (China) , Profacgen (United States) , ProteoGenix (France) , Peak Proteins Ltd. (United Kingdom) , Domainex Ltd. (United Kingdom) , Jena Bioscience GmbH (Germany)
Select User Access Type

Key Highlights of Report


Sep 2021 152 Pages 72 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Protein Therapeutic Market Quantitative research analysis
Global Protein Therapeutic Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Protein Therapeutic market is expected to see a CAGR of % during projected year 2020 to 2026.
Top performing companies in the Global Protein Therapeutic market are Merck KGaA (Germany), Thermo Fisher Scientific Inc. (United States), Becton, Dickinson & Company (United States), Agilent Technologies, Inc. (United States), QIAGEN N.V. (Netherlands), Takara Bio Inc. (Japan), Lonza Group Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (United States), GenScript Biotech Corporation (China), Lucigen Corporation (United States), Synthetic Genomics Inc. (United States), Promega Corporation (United States), New England Biolabs, Inc. (United States) and Sengenics (Singapore), to name a few.
North America is dominating the Protein Therapeutic Market.

Know More About Global Protein Therapeutic Market Report?

Have a Query? Click Here

Other Related Reports

Pet Ear Care Products Comprehensive Study by Type (Ear Cleansing Solution (Medicated, OTC (Over the Counter)), Ear Cleaner Wipes, Others), Application (Dogs, Cats, Others), Sales Channel (Online Sale...
$ 3500
Undegradable Protein Comprehensive Study by Type (Plant-based, Animal Based), Application (Aquaculture, Others), Distribution Channel (Online Sales Channel, Offline Sales Channel) Players and Region ...
$ 3500
Montelukast API Comprehensive Study by Type (Montelukast Sodium Amorphous, Montelukast Sodium Crystalline), Application (Asthma,, Allergic Rhinitis, Bronchospasm, Urticaria, Others), Dosage Form (Tab...
$ 3350
Drug & Pharmaceuticals & Cosmetics Retail Comprehensive Study by Type (Cosmetic, Pharmaceutical), Application (Child, Women, Men), Channel (Direct Sales, Distribution Channel) Players and Region - Gl...
$ 3400
Immune Boosting Supplement Comprehensive Study by Type (Vitamin C Supplements, Vitamin D Supplements, Vitamin B Supplements, Selenium Supplements, Zinc Supplements, Herbal Supplements, Probiotic Supp...
$ 3800
3D Printing Drug Comprehensive Study by Type (Spritam, Others), Application (Neurology, Hearing and Audibility Aid, Dental, Medical Implants, Others), End User (Hospitals, Clinics and, Research Labor...
$ 3800